M. Naomi Horiba

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison et al. · Journal of Clinical Oncology · 2015 · 544 citations

Medicine, Oncology, Pharmacology +17

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

Ulka N. Vaishampayan, Angelika M. Burger, Edward A. Sausville et al. · Clinical Cancer Research · 2010 · 63 citations · Full text

Medicine, Oncology, Pharmacology +15

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Timil H. Patel, Leigh Marcus, M. Naomi Horiba et al. · Clinical Cancer Research · 2022 · 57 citations · Full text

Medicine, Oncology, Pharmacology +13

Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.

Daniel Virgil Thomas Catenacci, Nathan Bahary, Sreenivasa Nattam et al. · Journal of Clinical Oncology · 2013 · 39 citations

Medicine, Oncology, Pharmacology +15

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, <i>HER2</i> -Positive <i>RAS</i> Wild-Type Colorectal Cancer

Sandra J. Casak, M. Naomi Horiba, Mengdie Yuan et al. · Clinical Cancer Research · 2023 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8